A New Therapeutic Approach Using a Schizophyllan-based Drug Delivery System for Inflammatory Bowel Disease
Antisense technologies for the targeted inhibition of gene expression could provide an effective strategy for the suppression of inflammation. However, the effective use of antisense oligonucleotides (ODN) has been limited because of several problems. Therefore, a delivery system for antisense ODNs...
Gespeichert in:
| Veröffentlicht in: | Molecular therapy 2012-06, Vol.20 (6), p.1234-1241 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1241 |
|---|---|
| container_issue | 6 |
| container_start_page | 1234 |
| container_title | Molecular therapy |
| container_volume | 20 |
| creator | Takedatsu, Hidetoshi Mitsuyama, Keiichi Mochizuki, Shinichi Kobayashi, Teppei Sakurai, Kazuo Takeda, Hiroshi Fujiyama, Yoshihide Koyama, Yoshikazu Nishihira, Jun Sata, Michio |
| description | Antisense technologies for the targeted inhibition of gene expression could provide an effective strategy for the suppression of inflammation. However, the effective use of antisense oligonucleotides (ODN) has been limited because of several problems. Therefore, a delivery system for antisense ODNs that enhances antisense stability, while maintaining the specificity of antisense for its target RNA or DNA is needed. We have developed a delivery system for antisense ODN using schizophyllan (SPG), a polysaccharide that belongs to the β-(1-3) glucan family. This system has several advantages enabling the effective suppression of targeted RNA or DNA: the SPG complex is stable in vivo and does not dissolve in the presence of deoxyribonuclease, and the SPG complex is effectively taken up into macrophages by phagocytosis through Dectin-1. Macrophage-migration inhibitory factor (MIF), which is mainly produced by macrophages has been shown to have a pathogenetic role in inflammatory bowel disease (IBD). We developed a technique to create an SPG complex that highly conformed to the antisense MIF. The administration of antisense MIF/SPG complex effectively suppressed MIF production and significantly ameliorated intestinal inflammation. Our result demonstrated a possible new therapeutic approach, i.e., the administration of antisense MIF/SPG complex, for the treatment of IBD. |
| doi_str_mv | 10.1038/mt.2012.24 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3369296</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1525001616325473</els_id><sourcerecordid>1668268197</sourcerecordid><originalsourceid>FETCH-LOGICAL-c550t-720e72061ae67d6e715bb5d716ddb13e67cae4ac8eb62b04814b4d2dc94be2f23</originalsourceid><addsrcrecordid>eNptkU1v1DAQhi0EoqVw4QcgS1wQUra24zjJBWnbBVqpgkPbs-WPycarJA52stXy6_Fqy6qgHqwZzTx-NTMvQu8pWVCSV-f9tGCEsgXjL9ApLViREcL4y2NOxQl6E-MmZbSoxWt0wliec8LYKdos8Q94wHctBDXCPDmDl-MYvDItvo9uWGOFb03rfvux3XWdGjKtIli8CvMar6BzWwg7fLuLE_S48QFfD02n-l5NPtUv_AN0eOUipE9v0atGdRHePcYzdP_t693lVXbz8_v15fImM0VBpqxkBNITVIEorYCSFloXtqTCWk3zVDQKuDIVaME04RXlmltmTc01sIblZ-jLQXecdQ_WwDAF1ckxuF6FnfTKyX87g2vl2m9lnoua1SIJfHoUCP7XDHGSvYsG9tuDn6OkQlRMVLQuE_rxP3Tj5zCk9SQta0bKnNc8UZ8PlAk-xgDNcRhK5N5C2U9yb6Fke_jD0_GP6F_PEsAPAKQjbh0EGY2DwYB1AcwkrXfP6f4B70qp5Q</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1792073494</pqid></control><display><type>article</type><title>A New Therapeutic Approach Using a Schizophyllan-based Drug Delivery System for Inflammatory Bowel Disease</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>ProQuest Central UK/Ireland</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Takedatsu, Hidetoshi ; Mitsuyama, Keiichi ; Mochizuki, Shinichi ; Kobayashi, Teppei ; Sakurai, Kazuo ; Takeda, Hiroshi ; Fujiyama, Yoshihide ; Koyama, Yoshikazu ; Nishihira, Jun ; Sata, Michio</creator><creatorcontrib>Takedatsu, Hidetoshi ; Mitsuyama, Keiichi ; Mochizuki, Shinichi ; Kobayashi, Teppei ; Sakurai, Kazuo ; Takeda, Hiroshi ; Fujiyama, Yoshihide ; Koyama, Yoshikazu ; Nishihira, Jun ; Sata, Michio</creatorcontrib><description>Antisense technologies for the targeted inhibition of gene expression could provide an effective strategy for the suppression of inflammation. However, the effective use of antisense oligonucleotides (ODN) has been limited because of several problems. Therefore, a delivery system for antisense ODNs that enhances antisense stability, while maintaining the specificity of antisense for its target RNA or DNA is needed. We have developed a delivery system for antisense ODN using schizophyllan (SPG), a polysaccharide that belongs to the β-(1-3) glucan family. This system has several advantages enabling the effective suppression of targeted RNA or DNA: the SPG complex is stable in vivo and does not dissolve in the presence of deoxyribonuclease, and the SPG complex is effectively taken up into macrophages by phagocytosis through Dectin-1. Macrophage-migration inhibitory factor (MIF), which is mainly produced by macrophages has been shown to have a pathogenetic role in inflammatory bowel disease (IBD). We developed a technique to create an SPG complex that highly conformed to the antisense MIF. The administration of antisense MIF/SPG complex effectively suppressed MIF production and significantly ameliorated intestinal inflammation. Our result demonstrated a possible new therapeutic approach, i.e., the administration of antisense MIF/SPG complex, for the treatment of IBD.</description><identifier>ISSN: 1525-0016</identifier><identifier>EISSN: 1525-0024</identifier><identifier>DOI: 10.1038/mt.2012.24</identifier><identifier>PMID: 22334022</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Animals ; Cells, Cultured ; Colitis - chemically induced ; Colitis - metabolism ; Colitis - therapy ; Cytokines - metabolism ; Dextran Sulfate - adverse effects ; Disease Models, Animal ; Drug Delivery Systems - methods ; Female ; Humans ; Inflammatory bowel disease ; Inflammatory Bowel Diseases - chemically induced ; Inflammatory Bowel Diseases - metabolism ; Inflammatory Bowel Diseases - therapy ; Intestinal Mucosa ; Lectins, C-Type - metabolism ; Macrophage Migration-Inhibitory Factors - chemistry ; Macrophage Migration-Inhibitory Factors - metabolism ; Macrophages - drug effects ; Macrophages - metabolism ; Mice ; Mice, Inbred C57BL ; Oligonucleotides, Antisense - administration & dosage ; Oligonucleotides, Antisense - chemistry ; Original ; Sizofiran - administration & dosage ; Sizofiran - chemistry</subject><ispartof>Molecular therapy, 2012-06, Vol.20 (6), p.1234-1241</ispartof><rights>2012 The American Society of Gene & Cell Therapy</rights><rights>Copyright Nature Publishing Group Jun 2012</rights><rights>Copyright © 2012 The American Society of Gene & Cell Therapy 2012 The American Society of Gene & Cell Therapy</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c550t-720e72061ae67d6e715bb5d716ddb13e67cae4ac8eb62b04814b4d2dc94be2f23</citedby><cites>FETCH-LOGICAL-c550t-720e72061ae67d6e715bb5d716ddb13e67cae4ac8eb62b04814b4d2dc94be2f23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3369296/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/1792073494?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793,64385,64387,64389,72469</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22334022$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Takedatsu, Hidetoshi</creatorcontrib><creatorcontrib>Mitsuyama, Keiichi</creatorcontrib><creatorcontrib>Mochizuki, Shinichi</creatorcontrib><creatorcontrib>Kobayashi, Teppei</creatorcontrib><creatorcontrib>Sakurai, Kazuo</creatorcontrib><creatorcontrib>Takeda, Hiroshi</creatorcontrib><creatorcontrib>Fujiyama, Yoshihide</creatorcontrib><creatorcontrib>Koyama, Yoshikazu</creatorcontrib><creatorcontrib>Nishihira, Jun</creatorcontrib><creatorcontrib>Sata, Michio</creatorcontrib><title>A New Therapeutic Approach Using a Schizophyllan-based Drug Delivery System for Inflammatory Bowel Disease</title><title>Molecular therapy</title><addtitle>Mol Ther</addtitle><description>Antisense technologies for the targeted inhibition of gene expression could provide an effective strategy for the suppression of inflammation. However, the effective use of antisense oligonucleotides (ODN) has been limited because of several problems. Therefore, a delivery system for antisense ODNs that enhances antisense stability, while maintaining the specificity of antisense for its target RNA or DNA is needed. We have developed a delivery system for antisense ODN using schizophyllan (SPG), a polysaccharide that belongs to the β-(1-3) glucan family. This system has several advantages enabling the effective suppression of targeted RNA or DNA: the SPG complex is stable in vivo and does not dissolve in the presence of deoxyribonuclease, and the SPG complex is effectively taken up into macrophages by phagocytosis through Dectin-1. Macrophage-migration inhibitory factor (MIF), which is mainly produced by macrophages has been shown to have a pathogenetic role in inflammatory bowel disease (IBD). We developed a technique to create an SPG complex that highly conformed to the antisense MIF. The administration of antisense MIF/SPG complex effectively suppressed MIF production and significantly ameliorated intestinal inflammation. Our result demonstrated a possible new therapeutic approach, i.e., the administration of antisense MIF/SPG complex, for the treatment of IBD.</description><subject>Animals</subject><subject>Cells, Cultured</subject><subject>Colitis - chemically induced</subject><subject>Colitis - metabolism</subject><subject>Colitis - therapy</subject><subject>Cytokines - metabolism</subject><subject>Dextran Sulfate - adverse effects</subject><subject>Disease Models, Animal</subject><subject>Drug Delivery Systems - methods</subject><subject>Female</subject><subject>Humans</subject><subject>Inflammatory bowel disease</subject><subject>Inflammatory Bowel Diseases - chemically induced</subject><subject>Inflammatory Bowel Diseases - metabolism</subject><subject>Inflammatory Bowel Diseases - therapy</subject><subject>Intestinal Mucosa</subject><subject>Lectins, C-Type - metabolism</subject><subject>Macrophage Migration-Inhibitory Factors - chemistry</subject><subject>Macrophage Migration-Inhibitory Factors - metabolism</subject><subject>Macrophages - drug effects</subject><subject>Macrophages - metabolism</subject><subject>Mice</subject><subject>Mice, Inbred C57BL</subject><subject>Oligonucleotides, Antisense - administration & dosage</subject><subject>Oligonucleotides, Antisense - chemistry</subject><subject>Original</subject><subject>Sizofiran - administration & dosage</subject><subject>Sizofiran - chemistry</subject><issn>1525-0016</issn><issn>1525-0024</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNptkU1v1DAQhi0EoqVw4QcgS1wQUra24zjJBWnbBVqpgkPbs-WPycarJA52stXy6_Fqy6qgHqwZzTx-NTMvQu8pWVCSV-f9tGCEsgXjL9ApLViREcL4y2NOxQl6E-MmZbSoxWt0wliec8LYKdos8Q94wHctBDXCPDmDl-MYvDItvo9uWGOFb03rfvux3XWdGjKtIli8CvMar6BzWwg7fLuLE_S48QFfD02n-l5NPtUv_AN0eOUipE9v0atGdRHePcYzdP_t693lVXbz8_v15fImM0VBpqxkBNITVIEorYCSFloXtqTCWk3zVDQKuDIVaME04RXlmltmTc01sIblZ-jLQXecdQ_WwDAF1ckxuF6FnfTKyX87g2vl2m9lnoua1SIJfHoUCP7XDHGSvYsG9tuDn6OkQlRMVLQuE_rxP3Tj5zCk9SQta0bKnNc8UZ8PlAk-xgDNcRhK5N5C2U9yb6Fke_jD0_GP6F_PEsAPAKQjbh0EGY2DwYB1AcwkrXfP6f4B70qp5Q</recordid><startdate>20120601</startdate><enddate>20120601</enddate><creator>Takedatsu, Hidetoshi</creator><creator>Mitsuyama, Keiichi</creator><creator>Mochizuki, Shinichi</creator><creator>Kobayashi, Teppei</creator><creator>Sakurai, Kazuo</creator><creator>Takeda, Hiroshi</creator><creator>Fujiyama, Yoshihide</creator><creator>Koyama, Yoshikazu</creator><creator>Nishihira, Jun</creator><creator>Sata, Michio</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><general>Nature Publishing Group</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>5PM</scope></search><sort><creationdate>20120601</creationdate><title>A New Therapeutic Approach Using a Schizophyllan-based Drug Delivery System for Inflammatory Bowel Disease</title><author>Takedatsu, Hidetoshi ; Mitsuyama, Keiichi ; Mochizuki, Shinichi ; Kobayashi, Teppei ; Sakurai, Kazuo ; Takeda, Hiroshi ; Fujiyama, Yoshihide ; Koyama, Yoshikazu ; Nishihira, Jun ; Sata, Michio</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c550t-720e72061ae67d6e715bb5d716ddb13e67cae4ac8eb62b04814b4d2dc94be2f23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Animals</topic><topic>Cells, Cultured</topic><topic>Colitis - chemically induced</topic><topic>Colitis - metabolism</topic><topic>Colitis - therapy</topic><topic>Cytokines - metabolism</topic><topic>Dextran Sulfate - adverse effects</topic><topic>Disease Models, Animal</topic><topic>Drug Delivery Systems - methods</topic><topic>Female</topic><topic>Humans</topic><topic>Inflammatory bowel disease</topic><topic>Inflammatory Bowel Diseases - chemically induced</topic><topic>Inflammatory Bowel Diseases - metabolism</topic><topic>Inflammatory Bowel Diseases - therapy</topic><topic>Intestinal Mucosa</topic><topic>Lectins, C-Type - metabolism</topic><topic>Macrophage Migration-Inhibitory Factors - chemistry</topic><topic>Macrophage Migration-Inhibitory Factors - metabolism</topic><topic>Macrophages - drug effects</topic><topic>Macrophages - metabolism</topic><topic>Mice</topic><topic>Mice, Inbred C57BL</topic><topic>Oligonucleotides, Antisense - administration & dosage</topic><topic>Oligonucleotides, Antisense - chemistry</topic><topic>Original</topic><topic>Sizofiran - administration & dosage</topic><topic>Sizofiran - chemistry</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Takedatsu, Hidetoshi</creatorcontrib><creatorcontrib>Mitsuyama, Keiichi</creatorcontrib><creatorcontrib>Mochizuki, Shinichi</creatorcontrib><creatorcontrib>Kobayashi, Teppei</creatorcontrib><creatorcontrib>Sakurai, Kazuo</creatorcontrib><creatorcontrib>Takeda, Hiroshi</creatorcontrib><creatorcontrib>Fujiyama, Yoshihide</creatorcontrib><creatorcontrib>Koyama, Yoshikazu</creatorcontrib><creatorcontrib>Nishihira, Jun</creatorcontrib><creatorcontrib>Sata, Michio</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Molecular therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Takedatsu, Hidetoshi</au><au>Mitsuyama, Keiichi</au><au>Mochizuki, Shinichi</au><au>Kobayashi, Teppei</au><au>Sakurai, Kazuo</au><au>Takeda, Hiroshi</au><au>Fujiyama, Yoshihide</au><au>Koyama, Yoshikazu</au><au>Nishihira, Jun</au><au>Sata, Michio</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A New Therapeutic Approach Using a Schizophyllan-based Drug Delivery System for Inflammatory Bowel Disease</atitle><jtitle>Molecular therapy</jtitle><addtitle>Mol Ther</addtitle><date>2012-06-01</date><risdate>2012</risdate><volume>20</volume><issue>6</issue><spage>1234</spage><epage>1241</epage><pages>1234-1241</pages><issn>1525-0016</issn><eissn>1525-0024</eissn><abstract>Antisense technologies for the targeted inhibition of gene expression could provide an effective strategy for the suppression of inflammation. However, the effective use of antisense oligonucleotides (ODN) has been limited because of several problems. Therefore, a delivery system for antisense ODNs that enhances antisense stability, while maintaining the specificity of antisense for its target RNA or DNA is needed. We have developed a delivery system for antisense ODN using schizophyllan (SPG), a polysaccharide that belongs to the β-(1-3) glucan family. This system has several advantages enabling the effective suppression of targeted RNA or DNA: the SPG complex is stable in vivo and does not dissolve in the presence of deoxyribonuclease, and the SPG complex is effectively taken up into macrophages by phagocytosis through Dectin-1. Macrophage-migration inhibitory factor (MIF), which is mainly produced by macrophages has been shown to have a pathogenetic role in inflammatory bowel disease (IBD). We developed a technique to create an SPG complex that highly conformed to the antisense MIF. The administration of antisense MIF/SPG complex effectively suppressed MIF production and significantly ameliorated intestinal inflammation. Our result demonstrated a possible new therapeutic approach, i.e., the administration of antisense MIF/SPG complex, for the treatment of IBD.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>22334022</pmid><doi>10.1038/mt.2012.24</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1525-0016 |
| ispartof | Molecular therapy, 2012-06, Vol.20 (6), p.1234-1241 |
| issn | 1525-0016 1525-0024 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3369296 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; ProQuest Central UK/Ireland; PubMed Central; Alma/SFX Local Collection |
| subjects | Animals Cells, Cultured Colitis - chemically induced Colitis - metabolism Colitis - therapy Cytokines - metabolism Dextran Sulfate - adverse effects Disease Models, Animal Drug Delivery Systems - methods Female Humans Inflammatory bowel disease Inflammatory Bowel Diseases - chemically induced Inflammatory Bowel Diseases - metabolism Inflammatory Bowel Diseases - therapy Intestinal Mucosa Lectins, C-Type - metabolism Macrophage Migration-Inhibitory Factors - chemistry Macrophage Migration-Inhibitory Factors - metabolism Macrophages - drug effects Macrophages - metabolism Mice Mice, Inbred C57BL Oligonucleotides, Antisense - administration & dosage Oligonucleotides, Antisense - chemistry Original Sizofiran - administration & dosage Sizofiran - chemistry |
| title | A New Therapeutic Approach Using a Schizophyllan-based Drug Delivery System for Inflammatory Bowel Disease |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T17%3A24%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20New%20Therapeutic%20Approach%20Using%20a%20Schizophyllan-based%20Drug%20Delivery%20System%20for%20Inflammatory%20Bowel%20Disease&rft.jtitle=Molecular%20therapy&rft.au=Takedatsu,%20Hidetoshi&rft.date=2012-06-01&rft.volume=20&rft.issue=6&rft.spage=1234&rft.epage=1241&rft.pages=1234-1241&rft.issn=1525-0016&rft.eissn=1525-0024&rft_id=info:doi/10.1038/mt.2012.24&rft_dat=%3Cproquest_pubme%3E1668268197%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1792073494&rft_id=info:pmid/22334022&rft_els_id=S1525001616325473&rfr_iscdi=true |